**Name of Journal:** World Journal of Gastroenterology

**Manuscript NO:** 75498

**Manuscript Type:** MINIREVIEWS

**Title:** Liver Imaging-Reporting and Data System Criteria in Diagnosis of Hepatocellular Carcinoma in Clinical Practice: A Pictorial Minireview

**Running Title:** LI-RADS criteria in the diagnosis of HCC

**Authors:** Christina Liava, Emmanouil Sinakos, Elissavet Papadopoulou, Lamprini Giannakopoulou, Stamatia Potsi, Anestis Moutmtzouoglou, Anthi Chatziioannou, Loukas Stergioulas, Lydia Kalogeropoulou, Ioannis Dedes, Evangelos Akriviadis, Danai Chourmouzi
Abstract
Hepatocellular carcinoma (HCC) is reported to be the sixth most common cancer. Main risk factors associated with HCC development include hepatitis B virus, hepatitis C virus, alcohol consumption, aflatoxin B1, and nonalcoholic fatty liver disease (NAFLD). However, hepatocarcinogenesis is a complex multistep process. Various factors lead to hepatocyte malignant transformation and HCC development. Diagnosis and surveillance of HCC can be made with the use of liver ultrasound (US) every 6 mo. However, the sensitivity of this imaging method to detect HCC in a cirrhotic liver is limited, due to the abnormal liver parenchyma. Computer tomography (CT) and magnetic resonance imaging (MRI) are considered to be most useful tools for at-risk patients or patients with inadequate US. Liver biopsy is still used for diagnosis and prognosis of HCC in specific nodules that cannot be definitely characterized as HCC by imaging. Recently the American College of Radiology designed the Liver Imaging-Reporting and Data System (LI-RADS), which is a comprehensive system for standardized interpretation of CT and MRI liver examinations, that was first proposed in 2011. In 2018 it was integrated into the American Association for the Study of Liver Diseases (AASLD) guidance statement for HCC. LI-RADS is designed to ensure high sensitivity, precise categorization and high positive predictive value for diagnosis of HCC and is applied to “high-risk population” according to specific criteria. Most importantly LI-RADS criteria achieved international collaboration and consensus among liver experts around the world on the best practices for caring for patients with or at risk for HCC.

Key Words: Hepatocellular Carcinoma; Hepatocarcinogenesis; Computed tomography; Magnetic Resonance Imaging; LI-RADS

Liava C, Sinakos E, Papadopoulou E, Giannakopoulou L, Potsi S, Mountzouoglou A, Chatziioannou A, Stergioulas L, Kalogeropoulou L, Dedes I, Akriviadis E, Chourmouzi D. Liver Imaging-Reporting and Data System Criteria in Diagnosis of Hepatocellular
Carcinoma in Clinical Practice: A Pictorial Minireview. World J Gastroenterol 2022; In press

Core Tip: Worldwide hepatocellular carcinoma is the sixth most common malignancy and the fourth cause of death related to cancer. Over the past decades, there is a progress on the diagnosis and treatment possibilities of HCC. We herein review the available knowledge on the carcinogenesis, the surveillance of HCC and the relevant data with the LI-RADS algorithm that was recently integrated into American Association for the Study Liver Disease (AASLD) HCC clinical practice guidelines. LI-RADS aim to avoid false-positive examinations and to ensure high sensitivity and positive predictive value in high-risk population with simultaneous achievement of probabilistic categorization of the tumor.
INTRODUCTION

Hepatocellular carcinoma (HCC) is considered to be the sixth most frequent cancer and the third leading cause of cancer death worldwide\[1\]. Up to 90% of HCC cases arise on the background of established liver cirrhosis or advanced fibrosis, which has been developed due to a known etiology\[2\]. The most predominant risk factors for HCC worldwide are hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol consumption and nonalcoholic fatty liver disease (NAFLD)\[3\].

The prognosis of HCC is significantly influenced by the disease stage at the time of diagnosis. Patients with HCC detection at an early-stage can be treated with potentially curative therapies\[4\]. Imaging plays an important role in the early diagnosis of HCC, both in the context of surveillance strategies of at-risk populations and in the phase of confirmatory studies for a new liver nodule. Most importantly, imaging studies for the diagnosis of HCC, usually performed with computed tomography (CT) or magnetic resonance imaging (MRI), have approximately 100% specificity. Therefore, HCC belongs amongst few malignancies for which management can be established on the basis of noninvasive imaging, without histologic confirmation\[5\].

CT and MRI are extensively used in clinical practice for the diagnosis of HCC. However, their diagnostic accuracy is decreased when strong criteria are not applied. In addition, the variable algorithms and recommendations from different scientific societies have created some degree of confusion in the interpretation of the radiological findings. To standardize the performance of liver imaging in patients with risk factors for developing HCC, the American College of Radiology (ACR) introduced in 2011 the first version of Liver Imaging-Reporting and Data System (LI-RADS)\[6\]. The LI-RADS criteria was created to standardize the terminology used for HCC imaging, to allow probabilistic categorization and to provide personalized medical care\[7\]. It has been updated in 2013, 2014, 2017, and 2018 and is considered a dynamic document, which can be expanded and refined in response to new knowledge and user feedback\[8\].
In this pictorial review we analyze the rational for the radiological diagnosis of HCC, present the LI-RADS criteria and associate them with characteristic images per category in order to enhance the familiarization of clinicians with the use of this system in clinical practice.

HEPATOCELLCARCINOGENESIS AND IMAGING CORRELATES

Hepatocarcinogenesis is a complex multistep process characterized by alterations in several levels (molecular, cellular, and histologic levels). Chronic liver inflammation can lead to continuous cycles of persistent cell injury, death, and regeneration, causing subsequent genetic damage and epigenetic alterations of hepatocytes\[^{8}\]. Various factors lead to hepatocyte malignant transformation and HCC development, such as genetic susceptibility, mutual interplays between viral and non-viral risk factors, cellular microenvironment, immune cells, and the severity of the underlying chronic liver disease. It is known that an altered microenvironment play a significant role in all stages of neoplastic growth, from the early mutation stage, through to invasion and, eventually, to metastatic stage\[^{10,11}\].

The molecular pathogenesis of HCC varies according to the distinct aetiologies\[^{10}\]. HBV and HCV consist the two main viruses, which can be implicated in the development of HCC\[^{12}\]. HBV genome integration can target cancer-relevant genes, protein x (HBx) can alter the expression of growth-control genes and inactivate the tumour suppressor p53 leading to HCC development\[^{12,13}\]. On the other hand, HCV infection is not characterized by oncogenic effect, however mutations can result from oxidative stress caused by chronic inflammation\[^{12}\]. Alcohol-induced hepatocarcinogenesis is another risk factor for developing HCC. Chronic alcohol intake is associated with proinflammatory cytokines production and oxidative stress which can lead to the development of fibrosis, cirrhosis and ultimately HCC\[^{14}\]. Aflatoxin-B1 also plays a role in hepatocarcinogenesis. It is known that this fungal toxin is associated with a specific p53 mutation and activation of oncogenes such as the Human Harvey-ras proto-oncogene (\textit{HRAS})\[^{15,16}\].
Irrespective of etiology, cirrhosis is the main underlying cause for most HCC cases. It is known that during cirrhosis regenerating nodules are developed, which provide an appropriate microenvironment for the development of normal hepatocytes to dysplastic hepatocytes to neoplastic lesions and culminating in HCC, through the subsequent agglomeration of multiple DNA (deoxyribonucleic acid) alterations[17]. Histologically, abnormal precursor hepatic lesions, including cirrhotic nodules, low-grade dysplastic nodules (LGDN), and high-grade dysplastic nodules (HGDN), dedifferentiate and progressively develop to form early and eventually advanced HCCs[5]. This continuum biologic procedure may happen simultaneously at various rates in different parts of the liver.

During hepatocarcinogenesis the vascular supply of the nodules modifies together with malignant progression: the number of intranodular portal tracts diminishes progressively, while the number of unpaired arteries increases. Eventually, HCC is supplied mainly by the abnormal hepatic artery system via neoangiogenic unpaired arteries[18]. It is important for both clinicians and radiologists to understand these hemodynamic changes during hepatocarcinogenesis as these correlates with the enhancing pattern precursor hepatic lesions and finally of HCCs on imaging studies.

Arterial phase hyperenhancement and portal venous and/or delayed phases wash-out relative to the background liver on contrast enhanced multiphasic CT and MRI are the most important imaging features of HCC and correlated with the blood supply of the nodules with malignant transformation.

Features during hepatocarcinogenesis also include tumor capsule and fibrous septa formation, fat accumulation within hepatocytes during the early phases (dysplasia and early HCC) while fat usually regresses with the progression to overt HCC.

Iron may also accumulate within hepatocytes during the dysplastic phases of hepatocarcinogenesis and usually also regresses with progression to HCC. Finally, organic anionic transporting polypeptides expression declines during hepatocarcinogenesis (OATP8 expression levels decreases during hepatocarcinogenesis
prior to reduction in portal tracts and increases in unpaired arteries). It is worth noting that abnormal venous drainage of HCCs occurs during hepatocarcinogenesis from hepatic veins to sinusoids and then to portal veins, which may interpret why HCC has a tendency to spread through the portal venous system rather than hepatic veins.[3]

HCC DIAGNOSIS

Early diagnosis of HCC is enhanced by the use of surveillance strategies in certain populations that are at-risk for developing HCC. Typically these patients include cirrhotic patients with Child-Pugh stage A and B as well as cirrhotic patients with Child-Pugh stage C awaiting for liver transplantation[19,20]. Regarding patients with chronic hepatitis B, the use of risk scores (especially PAGE-B) is recommended to prioritize patients for surveillance[21]. Finally, patients with severe fibrosis are recommended to enter surveillance programs on an individual basis after careful assessment of their risk[19,20]. As far as the tools that should be used for surveillance, most international societies recommend only the use of abdominal ultrasound (US) every 6 months, as the use of alpha-fetoprotein (AFP) is still controversial[19,20]. CT or MRI may be utilized for surveillance in selected patients with inadequate US visualization or at high risk for inadequate US[20].

Once a new nodule is discovered in the liver of a cirrhotic patient, further imaging work-up with either CT or MRI is recommended[19,20]. These modalities are also the gold standard for HCC diagnosis outside the use of surveillance programs. The peculiar vascular derangement that occurs during hepatic carcinogenesis, as previously described, correlate with imaging phases and have led to the implementation of accurate non-invasive criteria for HCC diagnosis. Integration of LI-RADS v2018 into the American Association for the Study of Liver Diseases (AASLD) HCC clinical practice guidelines, was a major step. As a result, the AASLD management suggestions are directly associated with the LI-RADS categories[20].

The routine use of liver biopsy is not suggested for the diagnosis of HCC[20]. Biopsy shortcomings include risks associated with the procedure. Another important issue is
that small lesions which are <2 cm is often difficult to target in a cirrhotic liver leading to high false negatives. However, the role of tumor tissue analysis in HCC is essential in cases of a cirrhotic patient that lacks typical imaging characteristics or in case where molecular profiling is needed to determine systemic therapy options\textsuperscript{[24]}. It should be also noted that the diagnosis should be confirmed with pathology in non-cirrhotic patients\textsuperscript{[19]}. In all these cases pathological diagnosis of HCC should be based on International Consensus recommendations using the appropriate histopathological analysis and immunohistochemistry\textsuperscript{[22,23]}.

**DESCRIPTION OF LIRADS**

LI-RADS has provided a standardized guidance, which contributes to a universal language for liver imaging findings. All LI-RADS diagnostic tables can be found for free at the ACR website (https://www.acr.org/ClinicalResources/Reporting-and-Data-Systems/LI-RADS). By philosophy LI-RADS diagnostic algorithm is developed to ensure high specificity and positive predictive value (PPV) for HCC diagnosis to avoid false-positive examinations. To obtain a high positive predictive value, LI-RADS should be used only to populations at high risk for developing HCC\textsuperscript{[25]}. This “high-risk population” includes adult patients with liver cirrhosis (except for vascular causes of cirrhosis), chronic HBV infection with or without cirrhosis, and patients diagnosed with current or prior HCC (Figure 1 and 2)\textsuperscript{[26]}.

Determining patients who meet the at-risk criteria is not always easy. Cirrhotic patients are usually diagnosed based only on clinical signs, symptoms and diagnostic markers with or without histological confirmation.

Measurement of liver stiffness using FibroScan could be a useful predictor of HCC appearance in patients with chronic hepatitis B and/or C\textsuperscript{[27]}. If the patient is considered with a high pre-test probability of HCC, LI-RADS may be used with a recommendation that the referring physician confirms the patient’s risk status (Figure 3).
Although HCC may develop in patients with non-alcoholic fatty liver disease/steatohepatitis (NASH) without cirrhosis, sufficient data are lacking to support that LI-RADS would provide an adequately high PPV for HCC in this sub-cirrhotic population group\(^{[28]}\). LI-RADS does not apply to patients <18 years old and patients with liver cirrhosis due to vascular diseases (e.g., cardiac hepatopathy, Budd-Chiari syndrome), because the above mentioned diseases are characterized by hypervascular benign liver lesions in liver imaging, which raise the probability of false positive results and reduce the PPV for HCC diagnosis\(^{[17]}\).

**LI-RADS CATEGORIES**

LI-RADS CT/MRI Diagnostic Algorithm version 2018 (v2018) is characterized by eight diagnostic categories which are used to individual liver lesions with increasing probability of HCC and malignancy with higher categories. The several LI-RADS categories do not have an exact association to the histologic categories but instead reflect the probability of individual liver lesions being benign, HCC, or non-HCC malignancy.

The LI-RADS CT/MRI algorithm is used in a stepwise manner starting with LR-NC. It is followed by LR-TIV, LR-1, LR-2, and LR-M. Once the above categories are excluded, the CT/MRI diagnostic table is then used to determine an observation LR-3, LR-4, or LR-5 category (Figure 4). LI-RADS criteria uses the term observation to generically refer to an area with an imaging appearance that is distinctive from the rest of the liver. Such an area may be a true lesion or a pseudolesion.

**LR-NC: not categorizable**

CT and MR imaging need to meet minimal technical requirements to yield the desired diagnostic accuracy. For CT, multidetector CT (>8 detectors) is requisite, whereas for MRI, 1.5 or 3T magnets are required according to LI-RADS guidance. Administration of intravenous contrast and acquisition of a multiphase liver protocol including images...
before contrast, late hepatic arterial phase, portal venous phase, and delayed phase images is required to allow for diagnosis of HCC. The most important characteristic is the acquisition of a technically adequate and well-timed arterial phase.

LI-RADS guidance strongly suggests that imaging should be performed during the late arterial phase, i.e., when the hepatic artery and portal vein are both enhanced, as this correlates with the time when arterialized tumor tissue is maximally enhanced relative to background liver (Figure 5). If an observation cannot be categorized due to image degradation or omission then radiologists may choose to assign an LR-NC category (Figure 6).

LI-RADS currently does not provide guidance on scoring the severity of artifact. In these cases, radiologists should use their judgment in suggesting either repeat or alternative imaging within 3 months to better characterize the liver lesion.

**LR-TIV Tumor in vein**

The presence of tumor in vein should be ruled out. LR-TIV category is defined by definite enhancing tissue with a vein, indicating the presence of tumor in vein. Whenever is possible the most likely etiology of tumor in vein should be assigned (due to HCC or non-HCC malignancy) (Figure 7 and 8).

**LR-1 Definitely benign**

LR-1 is applied to observations that are benign. Management should be returned to routine surveillance at 6 months intervals.

**LR-2 Probably benign**

LR-2 is applied to observations that are probably benign. Management should be returned to routine surveillance at 6 months intervals (Figure 9).

**LR-M**
LR-M for HCC observations display imaging characteristics of malignancy but not features that are specific. The LR-M category was created to maintain the specificity of the LI-RADS guidance for diagnosis of HCC while not losing sensitivity for liver malignancies. LR-M features include a targetoid or non-targetoid mass with infiltrative appearance, marked diffusion restriction, necrosis, or other characteristics suggestive of non-HCC malignancy\textsuperscript{[28]}. Targetoid mass is defined by rim enhancement in the arterial phase, peripheral washout, and progressive central enhancement on delayed phases. Although any liver malignancy can appear with characteristics of LR-M, the most common entities in patients at increased risk for developing HCC are intrahepatic cholangiocarcinoma (CCA), combined tumors (CCA-HCC), and atypical HCC. LR-M observations are commonly biopsied to propose the appropriate treatment (Figure 10).

**LI-RADS diagnostic table**

If the above categories (LR-TIV, LR-M, LR-1 and LR-2) are considered and excluded, the radiologist should use the LI-RADS diagnostic criteria based on combinations of major imaging features. The diagnostic table includes the predominant imaging characteristics of HCC in order to generate categories ranging from intermediate probability to definite HCC (LR-3, LR-4, LR-5). For CT and MR imaging, the LI-RADS predominant characteristics consist of:

- Size
- Presence of non-rim arterial phase hyperenhancement (APHE). APHE is defined by the appearance of enhancement that is unequivocally significantly than that of the background liver\textsuperscript{[29]}. On MRI the enhancing portion must have higher intensity and on CT higher attenuation than background liver in the arterial phase.
- Non-peripheral washout. Nonperipheral “washout” is defined as a visually assessed temporal decrease in enhancement in whole or at least in part relative to composite liver tissue from earlier to later phase leading to hypoenhancement.
• Enhancing capsule. Enhancing “capsule” gives the meaning of a smooth, uniform, and sharply outlined area of enhancement around a liver lesion which is either thicker or more conspicuous than fibrotic tissue detected in chronic liver disease.

It is worth mentioning that no single major imaging characteristic in the algorithm is specific enough to categorize a liver lesion as LR-5 and that LI-RADS liver lesions less than 10 mm in diameter cannot be categorized as LR-5.

**LR-3 Intermediate probability of malignancy**
Liver lesions categorized as LR-3 have intermediate probability of being considered HCC and the recommendation is to undergo short follow-up imaging in 3 to 6 months (Figure 11 and 12).

**LR-4 Probably HCC**
Observations categorized as LR-4 have high probability of being considered definite HCC and the suggestion is for individualized multidisciplinary approach that may comprise biopsy, probable treatment, or follow-up (Figure 13).

**LR-5 Definitely HCC**
Worth noting that for LR-5 categorization, non-rim APHE must be present. The criteria for LR-5 category has a positive predictive value approaching 100% in patients at high risk for developing HCC. Liver lesions categorized as LR-5 are considered definite HCC and therefore staging and treatment is suggested without biopsy (Figure 14, 15, 16 and 17).

**Ancillary features (AFs)**
Ancillary features (AFs) can be used at the radiologist’s discretion to adapt the category and to enhance the ability for reaching the final diagnosis. Although ancillary features are an important component of LI-RADS, their impact may be small (Figure 13).
Various ancillary features likely can be taken out from LI-RADS criteria without compromising diagnostic performance[30].

Treatment response algorithm (TR LI-RADS)

LI-RADS treatment response guidance (LR-TR) offers imaging criteria for evaluation of the success rate of locoregional therapy (Figure 17, 18 and 19). However, the guidance is not created for evaluating the response to systemic therapy, which is often at the patient-level rather than a lesion-level evaluation.

LI-RADS IN CLINICAL PRACTICE

The LI-RADS “lexicon” provide strict diagnostic criteria and reporting guidelines in order to enhance the consistency and clarity of radiologist interpretation and reporting. Subsequently, the communication between radiologists and clinicians has been improved. The adoption of a universal liver imaging lexicon is of great importance. This lexicon was designed to standardize the terminology used to describe liver imaging findings and is suggested for use in various patient settings including patients with cirrhosis, chronic HBV infection, current or prior HCC and following loco-regional therapy to assess tumor response[31,32]. In this sense, the integration of LI-RADS into the AASLD HCC clinical practice guidelines was a major achievement. However, global unification of diagnostic algorithms of HCC is still an unmet need.

Variability in terminology and definitions creates confusion between clinicians and challenges the significance of the published literature. For example, multiple terms have been used to describe nodules without APHE that are hypointense in the hepatobiliary phase of a gadoxetate-enhanced MRI examination[33]. The LI-RADS Hepatobiliary Agent Working Group suggests standardized terminology for these nodules: “hepatobiliary phase hypointense nodules without APHE”. A single term with a uniform definition enhances the ability of scientific investigators to define and pool data associated with these nodules and assists radiologists and referring clinicians in interpreting their clinical significance[31]. However, there are still areas of uncertainty.
Non-cirrhotic patients at increased risk for developing HCC, such as those with chronic HCV infection or nonalcoholic steatohepatitis with advanced fibrosis, do not meet criteria for diagnosis of HCC with the use of LI-RADS. This is an example of an important gap in the generalized implementation of the LI-RADS criteria which necessitates further research.

CONCLUSION

The diagnosis of HCC in clinical practice is based on imaging, using mainly CT and MRI. As the early diagnosis of HCC is associated with the overall prognosis, accurate identification of potential malignant liver lesions using these modalities is essential. LI-RADS is a comprehensive guidance that provides standardized interpretation and reporting of CT and MR liver imaging. LI-RADS is suggested to be used only to patients at high risk for developing HCC in a step-wise fashion that analyzes all the relevant radiologic characteristics according to a pre-defined manner. Clinicians that care for patients with liver disease must be familiar with the characterization of liver lesions using the LI-RADS criteria as this offers correct assessment of liver lesions and truthful communication between specialties.
<table>
<thead>
<tr>
<th></th>
<th>Source</th>
<th>Similarity Index</th>
<th>PRIMARY SOURCES</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Guilherme Moura Cunha, Kathryn J. Fowler, Farid Abushamat, Claude B. Sirlin, Yuko Kono. &quot;Imaging Diagnosis of Hepatocellular Carcinoma&quot;, Clinics in Liver Disease, 2020</td>
<td>4%</td>
<td>162 words</td>
</tr>
<tr>
<td>2</td>
<td><a href="http://www.dovepress.com">www.dovepress.com</a></td>
<td>4%</td>
<td>158 words</td>
</tr>
<tr>
<td>3</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>4%</td>
<td>154 words</td>
</tr>
<tr>
<td>5</td>
<td>hrjournal.net</td>
<td>3%</td>
<td>101 words</td>
</tr>
<tr>
<td>7</td>
<td>onlinelibrary.wiley.com</td>
<td>2%</td>
<td>85 words</td>
</tr>
<tr>
<td>Rank</td>
<td>Source</td>
<td>Title</td>
<td>Words</td>
</tr>
<tr>
<td>------</td>
<td>-------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>11</td>
<td>pubs.rsna.org</td>
<td>Anna Darnell, Jordi Rimola, Ernest Belmonte, Enric Ripoll et al. &quot;Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients&quot;, European Radiology, 2021</td>
<td>24</td>
</tr>
<tr>
<td>12</td>
<td>doctorpenguin.com</td>
<td>Sara K. Nsibirwa, Jim Aizire, David L. Thomas, Ponsiano Ocama, Gregory D. Kirk. &quot;Advanced presentation and rapid progression to death irrespective of HIV status after hepatocellular carcinoma diagnosis in Kampala, Uganda&quot;, Cold Spring Harbor Laboratory, 2022</td>
<td>19</td>
</tr>
<tr>
<td>13</td>
<td>publine.xiahepublishing.com</td>
<td>Anna Darnell, Jordi Rimola, Ernest Belmonte, Enric Ripoll et al. &quot;Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients&quot;, European Radiology, 2021</td>
<td>27</td>
</tr>
<tr>
<td>15</td>
<td>link.springer.com</td>
<td>Sara K. Nsibirwa, Jim Aizire, David L. Thomas, Ponsiano Ocama, Gregory D. Kirk. &quot;Advanced presentation and rapid progression to death irrespective of HIV status after hepatocellular carcinoma diagnosis in Kampala, Uganda&quot;, Cold Spring Harbor Laboratory, 2022</td>
<td>27</td>
</tr>
<tr>
<td>16</td>
<td>rep.bsmu.by</td>
<td>Sara K. Nsibirwa, Jim Aizire, David L. Thomas, Ponsiano Ocama, Gregory D. Kirk. &quot;Advanced presentation and rapid progression to death irrespective of HIV status after hepatocellular carcinoma diagnosis in Kampala, Uganda&quot;, Cold Spring Harbor Laboratory, 2022</td>
<td>27</td>
</tr>
</tbody>
</table>


Tommaso Vincenzo Bartolotta, Adele Taibbi, Massimo Midiri, Roberto Lagalla. "Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?", Ultrasonography, 2019